Schering-Plough offers medicines in the following areas:

Allergy & Respiratory
Animal Health
Anti-Infectives
Arthritis & Immunology

Cancer Therapies
CAELYX (pegylated liposomal doxorubicin HCI) (Marketed internationally only)
INTRON A Injection (interferon alfa-2b recombinant)
Noxafil is manufactured by Schering Corporation, Kenilworth, NJ.
PDF INTRON A Prescribing Information (PDF 159K)
TEMODAR (temozolomide) Capsules
ETHYOL (amifostine) (Marketed internationally only)

Cholesterol-Lowering/Cardiovascular

Erectile Dysfunction
Levitra

Foot Care
Butenafine 1% cream (Lotrimin) for athlete's foot - Schering-Plough Health Care Products, Memphis TN.

Hepatitis
Skin Disorders & Sun Care

Global Headquarters
Schering-Plough Corporation World Headquarters
2000 Galloping Hill Road
Kenilworth, N.J. 07033-0530
Telephone: (908) 298-4000

Schering-Plough Corp. Profit
October 2006 - Schering-Plough Corp. said its quarterly profit soared on increased sales of the cholesterol medicines it shares with Merck & Co. Inc. and strong demand for its other drugs, sending shares higher. Schering-Plough Corp., continuing to deliver on a turnaround promised by Chief Executive Fred Hassan, said third-quarter net profit rose to $287 million, or 19 cents per share, up from $43 million, or 3 cents per share, a year ago, which included a large charge. Global sales, which officially do not include cholesterol drugs Zetia and Vytorin that are co-marketed under a joint venture with Merck , rose 13 percent to $2.6 billion. Sales were bolstered by growing demand for arthritis drug Remicade, Nasonex allergy spray and brain cancer treatment Temodar.